TSC Staff
An April 2 story, priceline.com Affirms Operating Profit Forecast, incorrectly stated that the company expects second-quarter revenue to increase 15% to 20% from the first quarter. In fact, priceline.com (PCLN:Nasdaq) expects first-quarter revenue to increase 15% to 20% from the fourth quarter, while second-quarter revenue should be 10% to 15% higher than the first quarter. (corrected April 2)
An April 4 SuperModels column by Jon Markman, Wanted: Homes for Orphaned Growth Stocks, incorrectly rendered Novell's (NOVL:Nasdaq) plans for its consulting and services business in relation to its software business. Novell said it is not leaving or transitioning from the software business in favor of consulting, but rather is growing and expanding its software business while increasing its consulting resources.
An April 5 Herb on TheStreet column, Will Pfizer Give Lilly a Run for Its Money?, mistakenly reported that Pfizer's (PFE:NYSE) rollout of its schizophrenia drug, Geodon, was imminent. In fact, Geodon already launched. In the same column, Fastenal (FAST:Nasdaq) was described as a maker of nuts and bolts. In fact, Fastenal is a reseller of nuts and bolts. (corrected April 6)
An April 6 Herb on TheStreet column, What's the Real Deal With Dell?, incorrectly quoted Tom Chanos as saying of Dell (DELL:Nasdaq), "They're going to have to increase sales by $1 billion a year to make 10% growth." In fact, Chanos said Dell would have to increase sales by $1 billion a quarter to make 10% growth. (corrected April 6)
RSS
